About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapies industry, dedicated to treating rare and serious diseases and passionate about improving the quality of life of patients throughout the world.
We trace our corporate roots back to Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine. Innovation remains a core value of the company today. The company recently changed its name from ZLB Behring as part of our alignment with our parent organisation, CSLTM, a specialty biopharmaceutical company with heritage of contributions to human health for more than 90 years.
CSL Behring's comprehensive line of therapies includes:
•Plasma-derived and recombinant coagulation factors for the treatment of haemophilia, von Willebrand disease and other bleeding disorders
•Immunoglobulins for the treatment of primary immune deficiency (PID), idiopathic thrombocytopenic purpura (ITP), Guillain-Barré Syndrome (GBS) and other disorders
•Anti-D immunoglobulin for the prevention of haemolytic disease of the newborn
•Treatment for thrombosis
Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois, in accordance with international safety and quality standards. The company also operates ZLB Plasma Services, one of the world's largest plasma collection networks throughout the United States and Germany. CSL Behring employs more than 6,000 people in 18 countries.
We are passionate about safety, quality and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to all who count on our products.